Fanapt® (iloperidone) one month injectable
Schizophrenia
In DevelopmentNot Specified
Key Facts
About Vanda Pharmaceuticals
Founded in 2003 and publicly traded on NASDAQ (VNDA), Vanda Pharmaceuticals leverages genetics and genomics to inform drug discovery and development. The company has achieved significant milestones with FDA approvals for Fanapt® (2009) and HETLIOZ® (2014), and continues to expand its pipeline with late-stage candidates like tradipitant and imsidolimab. Vanda's strategic focus combines commercial execution with a science-driven approach to address complex disorders in circadian rhythms, psychiatry, and inflammation.
View full company profileTherapeutic Areas
Other Schizophrenia Drugs
| Drug | Company | Phase |
|---|---|---|
| Luvadaxistat (NBI-1065845) | Neurocrine Biosciences | Phase 2 |
| Cariprazine (Vraylar/Reagila) | Richter Gedeon | Approved |
| Lu AG13909 (PDE10A Inhibitor) | Lundbeck | Phase 1 |
| LATUDA (lurasidone HCl) | Sumitomo Pharma | Approved/Commercial |
| REXULTI (brexpiprazole) | Sumitomo Pharma | Approved/Commercial |
| DSP-2230 (ulotaront) | Sumitomo Pharma | Phase 3 |
| RBP-7000 (risperidone depot) | Indivior PLC | Approved |
| COBENFY® (xanomeline/trospium) | Zai Lab | Approved |
| Undisclosed CNS Candidate | Alto Neuroscience | Phase 1 |
| HTL'149 | Nxera Pharma | Phase 1 |
| GPR52 Agonist | Nxera Pharma | Preclinical |
| Fanapt® (iloperidone) | Vanda Pharmaceuticals | Approved |